



Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 MPro by targeting the cysteine 145

Laurent Soulère, Thibaut Barbier, Yves Queneau

► To cite this version:

Laurent Soulère, Thibaut Barbier, Yves Queneau. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 MPro by targeting the cysteine 145. *Computational Biology and Chemistry*, 2021, 92, pp.107463. 10.1016/j.compbiolchem.2021.107463 . hal-03243702

HAL Id: hal-03243702

<https://hal.science/hal-03243702>

Submitted on 31 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Docking-based virtual screening studies aiming at the covalent inhibition of
SARS-CoV-2 M^{Pro} by targeting the cysteine 145**

Laurent Soullère ^{1*}, Thibaut Barbier ¹ and Yves Queneau ¹

¹ Univ Lyon, Université Claude Bernard Lyon 1, INSA Lyon, CPE Lyon, UMR 5246, CNRS, ICBMS, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires, Chimie Organique et Bioorganique, Bât. E. Lederer, 1 rue Victor Grignard F-69622 Villeurbanne.

* Correspondence: laurent.soullere@insa-lyon.fr (L.S.)

KEYWORDS. SARS-CoV-2; Covalent inhibitors; M^{Pro}; flexible docking; virtual screening.

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 which has infected millions of people worldwide. The main protease of SARS-CoV-2 (M^{Pro}) has been recognized as a key target for the development of antiviral compounds. Taking advantage of the X-ray crystal complex with reversible covalent inhibitors interacting with the catalytic cysteine 145 (Cys145), we explored flexible docking studies to select alternative compounds able to target this residue as covalent inhibitors. First, docking studies of three known electrophilic compounds led to results consistent with co-crystallized data validating the method for SARS-CoV-2 M^{Pro} covalent inhibition. Then, libraries of soft electrophiles (overall 41 757 compounds) were submitted to docking-based virtual screening resulting in the identification of 17 molecules having their electrophilic group close to the Cys145 residue. We also investigated flexible docking studies of a focused approved covalent drugs library including 32 compounds with various electrophilic functional groups. Among them, the calculations resulted in the identification of four compounds, namely dimethylfumarate, fosfomycin, ibrutinib and saxagliptin, able first, to bind to the active site of the protein and second, to form a covalent bond with the catalytic cysteine.

INTRODUCTION

COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).(Lai et al., 2020) In November 2020, this disease has infected more than 55 300 000 people worldwide, including more than 1 300 000 deaths (<https://covid19.who.int/>). Consequently, there is an urgent need to identify new anti-viral drugs targeting this virus. Several strategies for identifying coronavirus anti-viral drugs have been described in the literature and they have been recently reviewed by Thanigaimalai Pillaiyar and co-workers.(Pillaiyar et al., 2020) Among them, an important approach consist in inhibiting the SARS-CoV-2 main protease (M^{pro}) by peptide mimics or other types of compounds.(Lu et al., 2006; Pillaiyar et al., 2016) Several studies have been devoted to computational determination of potential inhibitors of the SARS-CoV-2 main protease such as computational drug repurposing studies,(Arun et al., 2020; Wang, 2020) structure-based virtual screening studies(Gahlawat et al., 2020; Ton et al., 2020) and docking studies of natural compounds.(Gentile et al., 2020; Ngo et al., 2020) A strategy of achieving irreversible inhibition of this protease has also been addressed by the design of compounds to create a covalent bond with the cysteine 145 residue (Cys145) of the catalytic dyad.(Pillaiyar, et al., 2020) While classical docking studies are widely reported in the literature,(Kitchen et al., 2004) docking studies for covalent protein inhibition are less common,(Kumalo et al., 2015; Sottriffer, 2018) in particular with SARS-CoV-2 main protease.(Liu et al., 2020; Paul et al., 2020) Despite covalent inhibition approaches are less studied because the requirement of a nucleophilic residue is a structural limitation and they can be considered as harmful, the resurgence of covalent drugs encourage to also consider covalent inhibition.(Dalton et al., 2020; Ghosh et al., 2019; Singh et al., 2011) Irreversible specific protein inhibitors are now reported, such as in the case of the Ras protein possessing a G12C mutation, a

promising example of potential anticancer strategy.(Goody et al., 2019) Recent studies describe the inactivation of the SARS-CoV-2 M^{Pro} with either the N3 inhibitor,(Jin et al., 2020) originally discovered for SARS-CoV,(Yang et al., 2005) or the alpha-ketoamide inhibitor **1** (Figure 1).(L. Zhang et al., 2020) These studies show the importance of the catalytic Cys145 residue to design covalent inhibitors. Taking advantage of the X-ray crystal structure of the complex M^{Pro}-compound **1**,(L. Zhang, et al., 2020) we report herein flexible docking studies to identify potential irreversible inhibitors using electrophilic compounds libraries.




Figure 1. Structure, representation of the alpha-ketoamide inhibitor 1 within the M^{Pro} active site with surface and hydrogen bonds network.(L. Zhang, et al., 2020)

MATERIALS AND METHODS

Proteins used in the present study

The main protein of SARS-CoV-2 M^{Pro} was obtained from the protein data bank (PDB code 6Y2F, 5RHF, 5REN, 5REK).

Docking studies of known covalent inhibitors 2-4 with crystallographic data

Compounds **2-4** were generated as 3D mol file using Arguslab(Thompson, 2004) and they were then docked within the M^{Pro} active site (PDB codes 5RHF, 5REN, 5REK respectively) using Arguslab software with the Argusdock engine with default parameters. The obtained binding modes were compared to crystallographic data to validate the method. The distance between the sulfur and the methylene group of the chloroacetamide group was monitored to establish the structural bases of the M^{Pro} covalent inhibition (distance < 4 Å).

Docking-based virtual screening of potential covalent inhibitors

Compounds libraries were obtained from PubChem using structure search of acrylamide, halogenoacetamide, cyanoacrylamide and vinylsulfonamide. Asinex and Enamine soft electrophilic compounds libraries were obtained from the corresponding website and hydrogen atoms were added using OpenBabel 2.4.1..(O'Boyle et al., 2011) Each compound from the different libraries (SDF file) were then docked within the M^{Pro} active site centered on the β-keto

amide **1** using Arguslab software with the Argusdock engine with default parameters. Based on their docking score, binding modes were analyzed for the 20 best compounds of each library. The distance between the sulfur and the electrophilic center was monitored and compounds were selected when a distance $< 4 \text{ \AA}$ was measured. Binding modes were examined with PyMOL and hydrogen bonds networks were generated using LigPlot +.(Laskowski et al., 2011) For all selected compounds, further flexible docking experiments with a genetic algorithm engine implemented in Arguslab were achieved to corroborate the docking results (see supplementary information).

Docking studies of the approved covalent drugs library

The library was constructed based on the list of covalent drugs established by Vasudevan and co-workers,(Vasudevan et al., 2019) from which β -lactam derivatives, drugs withdrawn from market and mechanism based covalent drugs were excluded. For five of the 29 remaining compounds, their metabolites which are the active covalent binders(Shin et al., 2013) were used in the library. Overall, 32 compounds were used for the docking studies. When available, the SDF file for each compound was obtained from PubChem and was converted to PDB file using Accelrys Visualizer 2.0. For omeprazole, lansoprazole, pantoprazole and rabeprazole active metabolites, they were drawn using Vega ZZ(Pedretti et al., 2002, 2004) and were saved as PDB files. The 32 compounds were then docked within the M^{Pro} active site centered on the β -keto amide **1** using Arguslab software(Thompson, 2004) with the Argusdock engine with default parameters. The distance between the sulfur and the electrophilic center was monitored and compounds were selected when a distance $< 4 \text{ \AA}$ was measured. Binding modes were examined with PyMOL and hydrogen bonds networks were generated using LigPlot +.(Laskowski and Swindells, 2011) Further flexible docking experiments with a genetic algorithm engine

implemented in Arguslab were achieved to corroborate the docking results (see supplementary information).

RESULTS AND DISCUSSION

When applicable, the search for covalent inhibitors by docking can be carried out according to the scheme depicted in Figure 2 by targeting a nucleophilic residue such as a cysteine residue. It is then necessary that the electrophilic center is placed at the vicinity of the thiol function of this residue. This approach can be investigated with the M^{Pro} protein that contains a catalytic cysteine residue (Cys145). In order to explore the potentialities to covalently inhibit M^{Pro} , a flexible docking of compounds was performed to establish the structural bases for binding recognition with high affinity to improve the selectivity to the molecular target to form the complex $M^{\text{Pro}} + I$. In a second time, examination of the potentialities of the covalent inhibition of this protein due to the formation of a covalent adduct $M^{\text{Pro}}-I$ can be examined. For this, the location of the electrophilic moiety of compounds, in particular the distance between the electrophilic center and the thiol of Cys145 has to be adequate (Y. Zhang et al., 2016) (Figure 2). As a consequence, we used standard docking experiments targeting Cys145 with a cutoff of 4 Å as a theoretical study.(Choi et al., 2016; Lin et al., 2011)





Figure 2. Docking studies for covalent inhibition of SARS-CoV-2 M^{Pro} by targeting the Cys145 residue.

Docking studies of known covalent inhibitors of SARS-CoV-2 M^{Pro}

In order to explore the potentialities to covalently inhibit SARS-CoV-2 M^{Pro}, we first studied docking of the covalent inhibitors **2-4** co-crystallized within the protease to establish the structural bases for the covalent inhibition of this protein.(Douangamath et al., 2020) In particular, the location of the electrophilic moiety of compounds i.e. the distance between the electrophilic center and the thiol of Cys145 was investigated. Docking experiments were thus conducted on these three compounds; the results are depicted in Figure 3. These experiments show consistent results with the crystallographic data (PDB codes 5RHF, 5REN, 5REK respectively) and show that the electrophilic center of compounds i.e. the methylene group of the chloroacetamide functional group is located at the vicinity of Cys145 with distance values between the carbon and the thiol atoms ranging from 2.83 Å to 3.19 Å.



136







137 Figure 3: Docking results (colored in cyan) obtained from docking experiments conducted with
 138 compounds **2-4** within the active site of M^{pro} (co-crystallized compounds are indicated in green
 139 for comparison). Distance (Å) between the thiol function of Cys145 and the electrophilic center
 140 is shown in red color.

141
142 Based on these docking experiments of compounds **2-4**, we defined the structural basis for the
143 covalent inhibition of M^{pro} as 1) binding the protein with a good affinity and 2) having an
144 adequate orientation of the electrophilic moiety towards Cys145 with a distance inferior to 4 Å
145 with the sulfur (Figure 2).

146
147 *Docking-based virtual screening studies for covalent inhibition of M^{Pro}*
148 We then investigated docking-based virtual screening studies for covalent inhibition of M^{Pro}
149 using libraries of electrophilic inhibitors (Table 1). A total of 41 757 compounds in diverse
150 libraries constructed from PubChem or available from Enamine or Asinex were employed for
151 docking simulations. Docking poses for compounds ranked in the top 20 in each library were
152 then examined to evaluate the distance between the electrophilic center and the sulfur atom.

153
154
155
156
157
158
159

160 **Table 1.** Potential covalent inhibitors libraries used in this study.

Compounds libraries	Structures	Compounds number/potential inhibitors	Adducts
PubChem acrylamide		3905/1	Michael adduct
PubChem halogenoacetamide		4281/2	Nucleophilic substitution
PubChem cyanoacrylamide		3356/1	Reversible covalent adduct
PubChem vinylsulfonamide		1070/2	Michael adduct
Asinex Soft electrophile	Diverse	8098/3	Structure dependent
Enamine Covalent Screening Library	Diverse	15684/2	Structure dependent
Enamine Halogenoacetamide		2210/4	Nucleophilic substitution
Enamine Acrylamide		3153/2	Michael adduct


161

162 Structures of all potential covalent inhibitors of M^{Pro} are shown in Figure 4. All compounds were

163 found to be aromatic ones with a high diversity of structures. Among the 17 compounds, three

164 compounds are structurally related to acrylamides, two to vinylsulfonamides and six to

165 electrophilic chlorinated compounds. An alkyne derivative and three activated cyano-compounds
 166 could be also identified as well as two cyanoacrylamides. These latter compounds are
 167 particularly interesting leading to reversible covalent inhibition.(Serafimova et al., 2012)



168
 169 **Figure 4.** Structures of potential covalent inhibitors of M^{Pro} , with PubChem CID number.

170 Binding mode of each compound was carefully examined in terms of hydrogen bonds with the
 171 protein M^{Pro}, and the distance between the thiol and the electrophilic center was also measured
 172 (Table 2). Hydrogen bonds numbers were ranging from one to six for the compound 134294169.
 173 The docking score was found to be variable depending of the compounds library and the
 174 structure of the compounds. These values were ranging from – 7.22 to – 10.41 kcal.mol⁻¹ for the
 175 compound 1102141.

176

177 **Table 2.** Potential covalent inhibitors of M^{Pro} : docking score, hydrogen bonds numbers and Sn
 178 indicates the binding pockets interacting with the ligands (L. Zhang, et al., 2020), sulfur –
 179 electrophilic group distances.

Compounds	Docking score (kcal.mol ⁻¹)	H-bonds numbers, Sn	Sulfur – electrophilic center distances (Å)
1658938	– 9.19	1, S1 S3 S4	3.62
1625245	– 9.83	3, S1 S3 S4	4.03
4868406	– 9.28	2, S1 S2 S4	3.40
68782938	– 9.21	5, S1 S2 S3 S4	3.48
2011299	– 10.32	3, S1 S2 S4	3.18
134294169	– 9.43	6, S1 S2 S3 S4	3.80
3207595	– 10.18	1, S1 S2 S4	3.46
54693381	– 9.99	3, S1 S2 S3	2.97
1102141	– 10.41	1, S1 S3 S4	3.82
132327024	– 7.22	3, S1	3.94

132349371	– 7.35	3, S1 S2 S3	3.76
2405938	– 8.19	3, S1 S2	3.27
2404847	– 7.94	1, S1 S2 S3	3.51
2513345	– 7.96	2, S1 S3	3.57
7788967	– 8.49	2, S1 S2 S3	3.89
53520431	– 8.81	3, S1 S3	2.27
91944335	– 8.39	4, S1 S2	3.99

180

181 As example, we chose to depict the binding modes of two compounds with high docking score
182 values. The binding modes of the compound 2011299, which exhibits a low distance between the
183 thiol and the electrophilic center and the one of the compound 134294169 with six hydrogen
184 bonds, are described in Figure 5. The two compounds fit well in the active site. The compound
185 2011299 interacts with the Gly143, Ser144 and Cys145 residues via hydrogen bonds and with a
186 distance of 3.18 Å between the sulfur and the electrophilic carbon atom of the cyanoacrylamide
187 functional group. This group is of particular interest by potentially promoting reversible covalent
188 inhibition. The compound 134294169 interacts tightly within the active site with the His 41,
189 Cys44, Tyr54, Gly143, Cys145 and Gln192 residues via six hydrogen bonds and with a distance
190 of 3.80 Å between the sulfur and the electrophilic carbon atom of the vinyl sulfonamide
191 functional group. We also mention the compound 1658938 with a valuable docking score and a
192 distance of 3.62 Å. Indeed, this compound shows a low cytotoxicity which has been
193 demonstrated in several bioassays (see PubChem bioassays 435019, 1825, 504648, 602141).

194








Figure 5. Binding modes of compounds 2011299 (A) and 134294169 (B) with the corresponding hydrogen bonds network.

Flexible docking studies of an approved covalent drugs library targeting the Cys145 residue


Based on the approach described in Figure 2, we investigated a library of known approved covalent drugs. For this, we used a list of 52 FDA (Food and Drug administration) approved drugs described by Anil Vasudevan and colleagues in 2019.(Vasudevan, et al., 2019) Among these, we excluded some molecules for our study, such as drugs withdrawn from the market and drugs with a mechanism-based inhibition, resulting in a small library of 32 compounds. On this library, the workflow described in Figure 2 was applied by means of flexible docking

experiments and subsequent distance measurement between the Cys145 residue and the electrophilic center. Following this experiment, four compounds showed interesting results and they are presented in Table 3.


Table 3. Potential approved drugs as covalent inhibitors of M^{Pro}: binding modes, hydrogen bonds numbers and Sn indicates the binding pockets interacting with the ligands (L. Zhang, et al., 2020), thiol – electrophilic group distances.

Compounds (electrophilic moiety)	Binding modes	H- bonds, Sn	S – electrophilic center distances
Dimethylfumarate  <chem>COC(=O)/C=C/C(=O)OC</chem> (α,β -unsaturated ester)(Torkildsen et al., 2016)		4, S1	2.98 Å
Fosfomycin  <chem>C1OC1P(=O)(O)O</chem> (epoxide)(Michalopoulos et al., 2011)		3, S1	3.73 Å

Ibrutinib




(acrylamide)(Burger et al., 2015)




5,
S1 S3 3.39 Å
S4

Saxagliptin



(nitrile)(Barnett, 2006)



4,
S1 S3 3.78 Å

213

214 Careful analysis of the proposed binding mode of these compounds with the corresponding
215 hydrogen bonds network revealed that they could be able to bind tightly within the M^{Pro} binding
216 site. The distance between the sulfur and the electrophilic center is ranging from 2.98 and 3.78 Å
217 showing their potentialities to act as covalent inhibitors. The 2D-representation is described in
218 Figure 6 for the four compounds, showing the hydrogen bonds networks.




Figure 6. 2D representation of the proposed binding modes of the four potential covalent inhibitors within the binding site of M^{Pro} : dimethylfumarate (A), fosfomycin (B), ibrutinib (C), saxagliptin (D).

These four compounds are approved drugs for a designated pathology (Table 4) and some literature data can be found about relationships between COVID-19 and these compounds. First, Vittorio Mantero and colleagues reported that the use of dimethylfumarate for patients suffering from multiple sclerosis seems to have a positive impact against COVID-19.(Mantero et al., 2020) For ibrutinib, two studies shows that this compound seems to have a protective role against COVID-19, although they hypothesize that it may be due to the anti-inflammatory effect of the Bruton's tyrosine kinase pathway inhibition.(Thibaud et al., 2020; Treon et al., 2020) For saxagliptin, Alicja Krejner-Bienias and colleagues hypothesized that antidiabetic drugs, gliptins, could prevent the virus from binding to dipeptidyl peptidase IV (DPP IV)(Krejner-Bienias et al., 2020) Saxagliptin could then have a double effect on both M^{Pro} and DPP IV. For fosfomycin, no relationship between this compound and COVID-19 can be found in the literature to date.

Table 4. Biological target and therapeutic domain for the proposed compounds.

International nonproprietary name	Biological Target	Therapeutic Domain
Dimethylfumarate	NF-κB activation	Multiple sclerosis
Fosfomycin	UDP-N-acetylglucosamine-3-enolpyruvyltransferase	Anti-infective
Ibrutinib	Bruton's tyrosine kinase (BTK)	Cancer
Saxagliptin	Dipeptidyl peptidase IV (DPP IV)	Anti-diabetic drug

238

239 **CONCLUSION**

240 To summarize, we described docking studies directed toward the identification of potential
241 covalent inhibitors of SARS-CoV-2 M^{Pro} with significant structural diversity by targeting the
242 cysteine 145 residue. A docking-based virtual screening approach of 41 757 compounds
243 belonging to libraries of soft electrophilic small molecules, allowed us to unveil 17 more
244 potential covalent inhibitors. Then, using a library of approved covalent drugs, four compounds
245 namely dimethylfumarate, fosfomycin, ibrutinib and saxagliptin were identified for their
246 theoretical ability to first bind to the active site of the protein and second to form a covalent bond
247 with the catalytic cysteine. This study provides structural insights in the covalent inhibition of
248 M^{Pro}, which might be useful in the search for therapeutic approaches fighting COVID-19.

249

250 **Conflicts of Interest**

251 None to declare.

252

253 **ACKNOWLEDGMENT**

254 The authors are grateful to CNRS, MESRI for financial support and to the MESRI for a
255 scholarship to Thibaut Barbier.

256

257 **REFERENCES**

258 Arun, K. G., Sharanya, C. S., Abhithaj, J., Francis, D., Sadasivan, C. 2020. Drug repurposing
 259 against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking
 260 and molecular dynamics with main protease as the target. *J. Biomol. Struct. Dyn.*, 1-12.

261 Barnett, A. 2006. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
 262 *Int. J. Clin. Pract.*, 60, 1454-1470.

263 Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P.,
 264 Bartlett, N. L., Li, J., Simpson, D., Grosicki, S., Devereux, S., McCarthy, H., Coutre, S.,
 265 Quach, H., Gaidano, G., Maslyak, Z., Stevens, D. A., Janssens, A., Offner, F., Mayer, J.,
 266 O'Dwyer, M., Hellmann, A., Schuh, A., Siddiqi, T., Polliack, A., Tam, C. S., Suri, D.,
 267 Cheng, M., Clow, F., Styles, L., James, D. F., Kipps, T. J. 2015. Ibrutinib as Initial
 268 Therapy for Patients with Chronic Lymphocytic Leukemia. *N. Engl. J. Med.*, 373, 2425-
 269 2437.

270 Choi, J. E., Kim, J. H., Song, N. Y., Suh, J., Kim, D. H., Kim, S. J., Na, H. K., Nadas, J., Dong,
 271 Z., Cha, Y. N., Surh, Y. J. 2016. 15-Deoxy- $\Delta(12,14)$ -prostaglandin J(2) stabilizes
 272 hypoxia inducible factor-1 α through induction of heme oxygenase-1 and direct
 273 modification of prolyl-4-hydroxylase 2. *Free Radic. Res.*, 50, 1140-1152.

274 Dalton, S. E., Campos, S. 2020. Covalent Small Molecules as Enabling Platforms for Drug
 275 Discovery. *Chembiochem*, 21, 1080-1100.

276 Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T., Lukacik, P., Owen, C. D., Resnick, E.,
 277 Strain-Damerell, C., Aimon, A., Ábrányi-Balogh, P., Brandão-Neto, J., Carbery, A.,
 278 Davison, G., Dias, A., Downes, T. D., Dunnett, L., Fairhead, M., Firth, J. D., Jones, S. P.,
 279 Keeley, A., Keserü, G. M., Klein, H. F., Martin, M. P., Noble, M. E. M., O'Brien, P.,
 280 Powell, A., Reddi, R. N., Skyner, R., Snee, M., Waring, M. J., Wild, C., London, N., von

281 Delft, F., Walsh, M. A. 2020. Crystallographic and electrophilic fragment screening of
 282 the SARS-CoV-2 main protease. *Nat. Commun.*, 11, 5047.

283 Gahlawat, A., Kumar, N., Kumar, R., Sandhu, H., Singh, I. P., Singh, S., Sjöstedt, A., Garg, P.
 284 2020. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the
 285 SARS-CoV-2 Main Protease. *J. Chem. Inf. Model.*

286 Gentile, D., Patamia, V., Scala, A., Sciortino, M. T., Piperno, A., Rescifina, A. 2020. Putative
 287 Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A
 288 Virtual Screening and Molecular Modeling Study. *Mar. Drugs*, 18, 225.

289 Ghosh, A. K., Samanta, I., Mondal, A., Liu, W. R. 2019. Covalent Inhibition in Drug Discovery.
 290 *ChemMedChem*, 14, 889-906.

291 Goody, R. S., Müller, M. P., Rauh, D. 2019. Mutant-Specific Targeting of Ras G12C Activity by
 292 Covalently Reacting Small Molecules. *Cell Chem Biol*, 26, 1338-1348.

293 Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C.,
 294 Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., Bai,
 295 F., Liu, H., Guddat, L. W., Xu, W., Xiao, G., Qin, C., Shi, Z., Jiang, H., Rao, Z., Yang,
 296 H. 2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. *Nature*,
 297 582, 289-293.

298 Kitchen, D. B., Decornez, H., Furr, J. R., Bajorath, J. 2004. Docking and scoring in virtual
 299 screening for drug discovery: methods and applications. *Nat Rev Drug Discov*, 3, 935-
 300 949.

301 Krejner-Bienias, A., Grzela, K., Grzela, T. 2020. Do novel drugs for diabetes help in COVID-
 302 19? Another brick in the wall? *J. Diabetes*, 12, 703-704.

303 Kumalo, H. M., Bhakat, S., Soliman, M. E. 2015. Theory and applications of covalent docking in
 304 drug discovery: merits and pitfalls. *Molecules*, 20, 1984-2000.

305 Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., Hsueh, P. R. 2020. Severe acute respiratory
 306 syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The
 307 epidemic and the challenges. *Int. J. Antimicrob. Agents*, 55, 105924.

308 Laskowski, R. A., Swindells, M. B. 2011. LigPlot+: multiple ligand-protein interaction diagrams
 309 for drug discovery. *J. Chem. Inf. Model.*, 51, 2778-2786.

310 Lin, H. L., Zhang, H., Pratt-Hyatt, M. J., Hollenberg, P. F. 2011. Thr302 is the site for the
 311 covalent modification of human cytochrome P450 2B6 leading to mechanism-based
 312 inactivation by tert-butylphenylacetylene. *Drug Metab. Dispos.*, 39, 2431-2439.

313 Liu, S., Zheng, Q., Wang, Z. 2020. Potential covalent drugs targeting the main protease of the
 314 SARS-CoV-2 coronavirus. *Bioinformatics*, 36, 3295-3298.

315 Lu, I. L., Mahindroo, N., Liang, P. H., Peng, Y. H., Kuo, C. J., Tsai, K. C., Hsieh, H. P., Chao,
 316 Y. S., Wu, S. Y. 2006. Structure-based drug design and structural biology study of novel
 317 nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. *J*
 318 *Med Chem*, 49, 5154-5161.

319 Mantero, V., Abate, L., Basilico, P., Balgera, R., Salmaggi, A., Nourbakhsh, B., Cordano, C.
 320 2020. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. *J.*
 321 *Neurol.*, 1-3.

322 Michalopoulos, A. S., Livaditis, I. G., Gougoutas, V. 2011. The revival of fosfomycin. *Int J*
 323 *Infect Dis*, 15, e732-739.

324 Ngo, S. T., Quynh Anh Pham, N., Thi Le, L., Pham, D. H., Vu, V. V. 2020. Computational
 325 Determination of Potential Inhibitors of SARS-CoV-2 Main Protease. J. Chem. Inf.
 326 Model.
 327 O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., Hutchison, G. R.
 328 2011. Open Babel: An open chemical toolbox. J. Cheminform., 3, 33.
 329 Paul, A. S., Islam, R., Parves, M. R., Mamun, A. A., Shahriar, I., Hossain, M. I., Hossain, M. N.,
 330 Ali, M. A., Halim, M. A. 2020. Cysteine focused covalent inhibitors against the main
 331 protease of SARS-CoV-2. J. Biomol. Struct. Dyn., 1-20.
 332 Pedretti, A., Villa, L., Vistoli, G. 2002. VEGA: a versatile program to convert, handle and
 333 visualize molecular structure on Windows-based PCs. J. Mol. Graph. Model., 21, 47-49.
 334 Pedretti, A., Villa, L., Vistoli, G. 2004. VEGA--an open platform to develop chemo-bio-
 335 informatics applications, using plug-in architecture and script programming. J. Comput.
 336 Aided Mol. Des., 18, 167-173.
 337 Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., Jung, S. H. 2016. An Overview of
 338 Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors:
 339 Peptidomimetics and Small Molecule Chemotherapy. J Med Chem, 59, 6595-6628.
 340 Pillaiyar, T., Meenakshisundaram, S., Manickam, M. 2020. Recent discovery and development
 341 of inhibitors targeting coronaviruses. Drug Discov Today, 25, 668-688.
 342 Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L.,
 343 McFarland, J. M., Miller, R. M., Frodin, M., Taunton, J. 2012. Reversible targeting of
 344 noncatalytic cysteines with chemically tuned electrophiles. Nat. Chem. Biol., 8, 471-476.
 345 Shin, J. M., Kim, N. 2013. J. Neurogastroenterol. Motil., 19, 25-35.

346 Singh, J., Petter, R. C., Baillie, T. A., Whitty, A. 2011. The resurgence of covalent drugs. *Nat*
347 *Rev Drug Discov*, 10, 307-317.

348 Sottriffer, C. 2018. Docking of Covalent Ligands: Challenges and Approaches. *Mol Inform*, 37,
349 e1800062.

350 Thibaud, S., Tremblay, D., Bhalla, S., Zimmerman, B., Sigel, K., Gabrilove, J. 2020. Protective
351 role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia
352 and COVID-19. *Br. J. Haematol.*, 190, e73-e76.

353 Thompson, M. A. 2004. ArgusLaB 4.0.1, Seattle, WA planetaria Software LLC

354 Ton, A. T., Gentile, F., Hsing, M., Ban, F., Cherkasov, A. 2020. Rapid Identification of Potential
355 Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.
356 *Mol. Inform.*, 39, e2000028.

357 Torkildsen, Ø., Myhr, K. M., Bø, L. 2016. Disease-modifying treatments for multiple sclerosis -
358 a review of approved medications. *Eur J Neurol*, 23 Suppl 1, 18-27.

359 Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrero, M. L.,
360 Meid, K., Yang, G. 2020. The BTK inhibitor ibrutinib may protect against pulmonary
361 injury in COVID-19-infected patients. *Blood*, 135, 1912-1915.

362 Vasudevan, A., Argiriadi, M. A., Baranczak, A., Friedman, M. M., Gavriluk, J., Hobson, A. D.,
363 Hulce, J. J., Osman, S., Wilson, N. S. (2019). Covalent binders in drug discovery. *Prog.*
364 *Med. Chem.*, pp. 1-62.

365 Wang, J. 2020. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19
366 (COVID-19) through Computational Drug Repurposing Study. *J. Chem. Inf. Model.*, 60,
367 3277-3286.

368 Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J.,
369 Hilgenfeld, R., Yuen, K. Y., Wong, L., Gao, G., Chen, S., Chen, Z., Ma, D., Bartlam, M.,
370 Rao, Z. 2005. Design of wide-spectrum inhibitors targeting coronavirus main proteases.
371 PLoS Biol., 3, e324.

372 Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K.,
373 Hilgenfeld, R. 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for
374 design of improved alpha-ketoamide inhibitors. Science, 368, 409-412.

375 Zhang, Y., Zhang, D., Tian, H., Jiao, Y., Shi, Z., Ran, T., Liu, H., Lu, S., Xu, A., Qiao, X., Pan,
376 J., Yin, L., Zhou, W., Lu, T., Chen, Y. 2016. Identification of Covalent Binding Sites
377 Targeting Cysteines Based on Computational Approaches. Mol. Pharm., 13, 3106-3118.

378

379